Welcome to our dedicated page for Bio Green Med Solution news (Ticker: BGMS), a resource for investors and traders seeking the latest updates and insights on Bio Green Med Solution stock.
Bio Green Med Solution, Inc. reports news about its transition from the former Cyclacel Pharmaceuticals business to a company focused on fire safety protection and distribution activities. The company completed the acquisition of Fitters Sdn. Bhd., a Malaysia-based fire safety materials and equipment business, and reports product revenue from sales and distribution of fire safety equipment.
Company updates also cover quarterly and annual financial results, the liquidation of its former U.K. subsidiary, the sale of its Plogosertib drug, cash position commentary, and business updates tied to its current fire protection products and services focus.
Bio Green Med Solution (NASDAQ: BGMS) reported Q1 2026 results and business updates. The company, now focused on fire safety protection and distribution, generated $0.8 million in fire safety product revenue and reported a net loss of $0.2 million.
Cash and cash equivalents were $3.3 million at March 31, 2026, with operating cash use of $0.3 million. General and administrative expenses fell to $0.4 million from $4.2 million a year earlier. Trading of its 6% Convertible Exchangeable Preferred Stock (BGMSP) was suspended and delisted, while a $0.15 quarterly dividend on BGMSP was paid May 1, 2026.
Bio Green Med Solution (NASDAQ: BGMS) reported Q4 and full-year 2025 results, highlighting the Sept 12, 2025 acquisition of Fitters, sale of plogosertib for $300,000 plus a potential $170,000 milestone, and liquidation of its U.K. subsidiary.
As of Dec 31, 2025 cash totaled $3.5M, product revenue from fire-safety sales was $0.7M, net loss for 2025 was $3.0M, and the company estimates cash runway into Q3 2026.
Bio Green Med Solution (NASDAQ: BGMS) reported Q3 results for the period ended September 30, 2025 and provided a business update.
Key facts: cash and cash equivalents of $3.8M (up from $3.1M at 12/31/24); estimated cash runway into the first quarter of 2026; net loss of $1.0M for Q3 2025 versus $2.0M a year earlier; product revenue from fire safety sales of $81k and cost of sales of $64k following the September acquisition of Fitters Sdn. Bhd.; R&D expense of $0 in Q3 2025 after liquidation of the UK subsidiary.
Corporate actions: a 1-for-15 reverse stock split effective July 7, 2025; sale of Plogosertib-related patents for $300k plus up to $170k in potential milestone payments; Fitters exchange resulted in Fitters owning approximately 19.99% of BGMS; two warrant exchange transactions converted warrants into an aggregate of 1,962,000 new shares.